Dr. Gary K. Schwartz

Cardiology
Cardiology Consultants Of Philadelphia PC
1703 S Broad St Ste 300, 
Philadelphia,, PA 
Accepting New Patients
Referral may be required
Before you request
Cardiology Consultants Of Philadelphia PC
1703 S Broad St Ste 300, 
Philadelphia,, PA 

Overview

Gary Schwartz is a Cardiologist practicing medicine in Philadelphia,, Pennsylvania.

His clinical expertise encompasses Neurofibromatosis, COVID-19, Atherosclerosis, Hepato-Pancreato-Biliary Surgery, and Liver Embolization.

He is actively involved in clinical research, co-authoring 303 peer reviewed articles and participating in 32 clinical trials. Dr. Schwartz is currently accepting new patients.

Specialties

Cardiology

Licenses

Internal Medicine in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Cardiology Consultants of Philadelphia PC
1703 S Broad St Ste 300, Philadelphia,, PA 19148

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

29 Clinical Trials

A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Genetic
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: August 20, 2026
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Drug, Other
Study Drug: Telaglenastat Hydrochloride
Study Phase: Phase 2
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Phase: Phase 1
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Other
Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction With the Hypomethylating Agent Azacitidine in Patients With Advanced Pancreatic Cancer After Failure of First-Line Therapy
Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction With the Hypomethylating Agent Azacitidine in Patients With Advanced Pancreatic Cancer After Failure of First-Line Therapy
Enrollment Status: Completed
Publish Date: January 27, 2026
Intervention Type: Drug
Study Drugs: Pembrolizumab, Azacitidine
Study Phase: Phase 2
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Drug, Procedure
Study Drugs: Pegylated arginine deiminase, Gemcitabine, Docetaxel
Study Phase: Phase 2
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: November 04, 2025
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

302 Total Publications

Enhancing Gemcitabine Uptake by Promoting Dimerization of the ENT1 Transporter Improves Sarcoma Patient Response Rate.
Enhancing Gemcitabine Uptake by Promoting Dimerization of the ENT1 Transporter Improves Sarcoma Patient Response Rate.
Journal: The Journal of clinical investigation
Published: September 03, 2026
Similar Doctors
Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required
Before you request

Penn Heart And Vascular Center

3400 Civic Center Boulevard, East Pavilion, 2nd Floor, 
Philadelphia, PA 
 (3.3 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Callans is a Cardiologist practicing medicine in Philadelphia, Pennsylvania. Dr. Callans is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Ventricular Tachycardia, Arrhythmias, Cardiomyopathy, Cardiac Ablation, and Pacemaker Implantation. Dr. Callans is board certified in Internal Medicine, 1989, Clinical Cardiac Electrophysiology, 1994, and Cardiovascular Disease, 1993. Dr. Callans is currently accepting new patients.

Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required
Before you request

Penn Heart And Vascular Center

3400 Civic Center Boulevard, East Pavilion, 2nd Floor, 
Philadelphia, PA 
 (3.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Saman Nazarian is a Cardiologist practicing medicine in Philadelphia, Pennsylvania. Dr. Nazarian is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Ventricular Tachycardia, Arrhythmias, Atrial Fibrillation, Cardiac Ablation, and Pacemaker Implantation. Dr. Nazarian is board certified in Cardiovascular Disease, 2006 and Clinical Cardiac Electrophysiology, 2008. Dr. Nazarian is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required
Before you request

Penn Heart And Vascular Center

3400 Civic Center Boulevard, East Pavilion, 2nd Floor, 
Philadelphia, PA 
 (3.3 miles away)
215-615-4949
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Anjali Owens is a Cardiologist practicing medicine in Philadelphia, Pennsylvania. Dr. Owens is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Cardiomyopathy, Hypertrophic Cardiomyopathy (HCM), Familial Hypertrophic Cardiomyopathy, Heart Transplant, and Cardiac Ablation. Dr. Owens is currently accepting new patients.

Frequently Asked Questions about Dr. Gary K. Schwartz

How do I make an appointment with Dr. Gary K. Schwartz?

You can book an appointment with Dr. Gary K. Schwartz by calling their office at 215-463-5333. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gary K. Schwartz a top-rated expert for Hepato-Pancreato-Biliary Surgery?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gary K. Schwartz is classified as an Experienced expert for Hepato-Pancreato-Biliary Surgery, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gary K. Schwartz specialize in?

While Dr. Gary K. Schwartz is a Cardiology, they have specific expertise in Hepato-Pancreato-Biliary Surgery, Neurofibromatosis, and COVID-19. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Cardiology.

Does Dr. Gary K. Schwartz participate in research or clinical trials?

Yes. Dr. Gary K. Schwartz has published 302 articles and abstracts on conditions like Hepato-Pancreato-Biliary Surgery. You can view a list of Dr. Gary K. Schwartz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gary K. Schwartz accept my insurance?

Dr. Gary K. Schwartz accepts most major insurance plans, including Highmark and Humana. We recommend calling the office directly at 215-463-5333 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schwartz's expertise for a condition
ConditionClose
        View All 31 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile